[1]袁 洋,魏雨菲,高稳稳,等.程序性细胞死亡受体1抑制剂nivolumab治疗肺癌研究进展[J].新乡医学院学报,2018,35(11):943-948.[doi:10.7683/xxyxyxb.2018.11.001.]
 N/A.N/A[J].Journal of Xinxiang Medical University,2018,35(11):943-948.[doi:10.7683/xxyxyxb.2018.11.001.]
点击复制

程序性细胞死亡受体1抑制剂nivolumab治疗肺癌研究进展
分享到:

《新乡医学院学报》[ISSN:1004-7239/CN:41-1186/R]

卷:
35
期数:
2018年11
页码:
943-948
栏目:
专题报告
出版日期:
2018-11-05

文章信息/Info

Title:
N/A
作者:
袁 洋魏雨菲高稳稳范庆玲于海川
(新乡医学院医学检验学院 河南省分子诊断与医学检验技术协同创新中心,河南 新乡 453003)
Author(s):
N/A
N/A
关键词:
肺癌程序性细胞死亡受体1程序性细胞死亡受体1抑制剂程序性细胞死亡受体-配体1nivolumab免疫疗法
Keywords:
N/A
分类号:
R734.2
DOI:
10.7683/xxyxyxb.2018.11.001.
文献标志码:
A
摘要:
肺癌是一种具有侵袭性的疾病,其对化学治疗反应敏感,但复发率高,因此,急需新的治疗策略来延缓肺癌的病程,以弥补化学治疗的不足。近年来,随着免疫检查点的发现,免疫疗法成为肿瘤治疗的一项革新技术和重要手段。程序性细胞死亡受体1(PD-1)抑制剂nivolumab是第1个人源化抗PD-1的单克隆抗体,可与PD-1结合而激活免疫细胞,增强免疫系统的抗肿瘤活性,在肺癌治疗中具有较好的效果,日益成为肿瘤治疗研究的焦点。本文对PD-1抑制剂nivolumab治疗肺癌的相关研究进展进行综述。
Abstract:
N/A

参考文献/References:

[1] SIEGEL R L,MILLER K D,JEMAL A.Cancer statistics,2015[J].CA Cancer J Clin,2015,65(1):5-29.
[2] HAIDONG H,YUNYE N,WEI Z,et al.Multiple guided technologies based on radial probe endobronchial ultrasound for the diagnosis of solitary peripheral pulmonary lesions:a single-center study[J].J Cancer,2017,8(17):3514-3521.
[3] OEZKAN F,KHAN A,ZAROGOULIDIS P,et al.Efficient utilization of EBUS-TBNA samples for both diagnosis and molecular analyses[J].Onco Targets Ther,2014,7:2061-2065.
[4] 黄志煜,李晖,范云.抗PD-1/PD-L1单抗治疗肺癌临床研究进展[J].中国肺癌杂志,2015,18(11):706-713.
[5] ISHIDA Y,AGATA Y,SHIBAHARA K,et al.Induced expression of PD-1,a novel member of the immunoglobulin gene superfamily,upon programmed cell death[J].EMBO J,1992,11(11):3887-3895.
[6] LATCHMAN Y,WOOD C R,CHERNOVA T,et al.PD-L2 is a second ligand for PD-1 and inhibits T cell activation[J].Nat Immunol,2001,2(3):261-268.
[7] WOO S R,TURNIS M E,GOLDBERG M V,et al.Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape[J].Cancer Res,2012,72(4):917-927.
[8] GUNTURI A,MCDERMOTT D F.Nivolumab for the treatment of cancer[J].Expert Opin Investig Drugs,2015,24(2):253-260.
[9] 王莉,张志叶.PD-1抑制剂新药nivolumab[J].中国新药杂志,2016,25(9):961-963.
[10] 张锦鹏,傅昭粤,宣国云,等.肿瘤免疫治疗的研究进展[J].转化医学电子杂志,2018,5(1):1-5.DOI:10.12095/j.issn.2095-6894.2018.01.001.
[11] PALUCKA A K,COUSSENS L M.The basis of oncoimmunology[J].Cell,2016,164(6):1233-1247.
[12] 王虹伊,陆军.肿瘤免疫治疗的临床研究进展[J].实用医学杂志,2018,34(6):917-919.
[13] CHEN L,HAN X.Anti-PD-1/PD-L1 therapy of human cancer:past,present,and future[J].J Clin Invest,2015,125(9):3384-3391.
[14] 殷宏玲,杨卫卫,赵红,等.PD-1/PD-L1抑制剂在肿瘤免疫治疗中的研究进展[J].延安大学学报(医学科学版),2018,16(1):90-94.
[15] YOKOSUKA T,TAKAMATSU M,KOBAYASHIIMANISHI W,et al.Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2[J].J Exp Med,2012,209(6):1201-1217.
[16] 王文超,汪宇,施乐华.PD-1/PD-L1信号通路及其在肿瘤免疫治疗中的作用[J].第二军医大学学报,2017,38(9):1190-1195.
[17] ZOU W,WOLCHOK J D,CHEN L.PD-L1(B7-H1) and PD-1 pathway blockade for cancer therapy:mechanisms,response biomarkers,and combinations[J].Sci Transl Med,2016,8(328):328-334.
[18] 雷泽民,余宗阳.非小细胞肺癌T细胞PD-1免疫靶向治疗研究现状与展望[J].中国肿瘤,2015,24(5):398-402.
[19] TUMEH P C,HARVIEW C L,YEARLEY J H,et al.PD-1 blockade induces responses by inhibiting adaptive immune resistance[J].Nature,2014,515(7528):568-571.
[20] DONG Y,SUN Q,ZHANG X.PD-1 and its ligands are important immune checkpoints in cancer[J].Oncotarget,2017,8(2):2171-2186.
[21] DONG H,ZHU G,TAMADA K,et al.B7-H1,a third member of the B7 family,co-stimulates T-cell proliferationand interleukin-10 secretion[J].Nat Med,1999,5(12):1365-1369.
[22] AZUMA T,YAO S,ZHU G,et al.B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells[J].Blood,2008,111(7):3635-3643.
[23] RIZIVI N A,MAZIERES J,PLANCHARD D,et al.Activity and safety of nivolumab,an anti-PD-1 immune checkpoint inhibitor,for patients with advanced,refractory squamous non-small-cell lung cancer (CheckMate 063):a phase 2,single-arm trial[J].Lancet Oncol,2015,16(3):257-265.
[24] RECK M,POPAT S,REINMUTH N,et al.Metastatic non-small-cell lung cancer (NSCLC):ESMO clinical practice guidelines for diagnosis,treatment and follow-up[J].Ann Oncol,2014,25(3):27-39.
[25] ZIELINSK C,KNAPP S,MASCAUX C,et al.Rationale for targeting the immune system through checkpoint molecule blockade in the treatment of non-small-cell lung cancer[J].Ann Oncol,2013,24(5):1170-1179.
[26] GETTINGER S N,HORN L,GANDHI L,et al.Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody,BMS-936558,ONO-4538) in patients with previously treated advanced non-small-cell lung cancer[J].J Clin Oncol,2015,33(18):2004-2012.
[27] LIM J S,SOO R A.Nivolumab in the treatment of metastatic squamous non-small cell lung cancer:a review of the evidence[J].Ther Adv Respir Dis,2016,10(5):444-454.
[28] ZAGO G,MULLER M,VAN DEN HEUVEL M,et al.New targeted treatments for non-small-cell lung cancer:role of nivolumab[J].Biologics,2016,10(8):103-117.
[29] GETTINGER S,HORN L,JACKMAN D,et al.Five-year follow-up of nivolumab in previously treated advanced non-small-cell lung cancer:results from the CA209-003 study[J].J Clin Oncol,2018,36(17):1675-1684.
[30] RIZIVI N A,MAZIERES J,PLANCHARD D,et al.Activity and safety of nivolumab,an anti-PD-1 immune checkpoint inhibitor,for patients with advanced,refractory squamous non-small-cell lung cancer (CheckMate 063):a phase 2,single-arm trial[J].Lancet Oncol,2015,16(3):257-265.
[31] LENA H,RIZVI N A,WOLF J,et al.137O:nivolumab in patients (pts) with advanced refractory squamous (SQ) non-small cell lung cancer (NSCLC):2-year follow-up from CheckMate 063 and exploratory cytokine profling analyses[J].J Thorac Oncol,2016,11(4):S115-S116.
[32] BRAHMER J,RECKAMP K L,BAAS P,et al.Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer[J].N Engl J Med,2015,373(2):123-135.
[33] VOKES E E,READY N,FELIP E,et al.Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057):3-year update and outcomes in patients with liver metastases[J].Ann Oncol,2018,29(4):959-965.
[34] GETTINGER S,RIZVI N A,CHOW L Q,et al.Nivolumab monotherapy for first-line treatment of advanced non-small-cell lung cancer[J].J Clin Oncol,2016,34(25):2980-2987.
[35] KILLOCK D.Lung cancer:frontline nivolumab-CheckMate 026 ends in stalemate[J].Nat Rev Clin Oncol,2017,14(8):458-459.
[36] HELLMANN M D,RIZVI N A,GOLDMAN J W,et al.Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012):results of an open-label,phase 1,multicohort study[J].Lancet Oncol,2017,18(1):31-41.
[37] HELLMANN M D,CIULEANU T E,PLUZANSKI A,et al.Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden[J].N Engl J Med,2018,378(22):2093-2104.
[38] WU Y,JU Q,QIAN B,et al.The effectiveness of PD-1 inhibitors in non-small cell lung cancer (NSCLC) patients of different ages[J].Oncotarget,2017,9(8):7942-7948.
[39] SIOCIMSKI M A,BONDARENKO I,KARASEVA N A,et al.Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer:final results of a phase Ⅲ trial[J].J Clin Oncol,2012,30(17):2055-2062.
[40] FORDE P M,CHAFT J E,SMITH K N,et al.Neoadjuvant PD-1 blockade in resectable lung cancer[J].N Engl J Med,2018,378(21):1976-1986.
[41] LIU J,BLAKE S J,YONG M C,et al.Improved efficacy of neoadjuvant compared to adjuvant immunotherapy to eradicate metastatic disease[J].Cancer Discov,2016,6(12):1382-1399.
[42] 张爽,柳菁菁,程颖.免疫检查点抑制剂在小细胞肺癌中的临床研究进展[J].中国肺癌杂志,2017,20(9):623-628.
[43] ANTONIA S J,LPEZ-MARTIN J A,BENDELL J,et al.Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032):a multicentre,open-label,phase 1/2 trial[J].Lancet Oncol,2016,17(7):883-895.
[44] HELLMANN M D,OTT P A,ZUGAZAGOITIA J,et al.Nivolumab(nivo)± ipilimumab (ipi) in advanced small-cell lung cancer (SCLC):first report of a randomized expansion cohortfrom CheckMate 032 [J].J Clin Oncol,2017,35:S8503.
[45] PAKKALA S,OWONIKOKO T K.Immune checkpoint inhibitors in small cell lung cancer[J].J Thorac Dis,2018,10(suppl 13):S460-S467.
[46] RECK M,RABE K F.Precision diagnosis and treatment for advanced non-small-cell lung cancer[J].N Engl J Med,2017,377(9):849-861.
[47] SUYAMA T,FUKUDA Y,SODA H,et al.Successful treatment with nivolumab for lung cancer with low expression of PD-L1 and prominent tumor-infiltrating B cells and immunoglobulin G[J].Thorac Cancer,2018,9(6):750-753.
[48] BOUTSIKOU E,DOMVRI K,HARDAVELLA G,et al.Tumour necrosis factor,interferon-gamma and interleukins as predictive markers of antiprogrammed cell-death protein-1 treatment in advanced non-small cell lung cancer:a pragmatic approach in clinical practice[J].Ther Adv Med Oncol,2018,10:1-8.

相似文献/References:

[1]杜华贞,和瑞芝,千高峰,等.肺癌痰液脱落细胞学检查——附164例分析[J].新乡医学院学报,1988,(02):022.
[2]张彩平,范迎胜,李 新,等.肺癌患者医院真菌感染原因调查分析[J].新乡医学院学报,2002,(05):416.
[3]朱自德.青年肺癌1O例临床分析[J].新乡医学院学报,2003,(03):213.
[4]朱自德.青年肺癌10例临床分析[J].新乡医学院学报,2003,(03):213.
[5]房秀清,尹丽欣,钞丽红.胸腔积液中癌胚抗原及CA125 和CA153 联合检测对肺癌的诊断意义[J].新乡医学院学报,2012,(06):428.
[6]牛慧彦,王鑫,张萌,等.雷帕霉素联合多西紫杉醇对肺癌细胞增殖和凋亡的影响[J].新乡医学院学报,2012,(01):000.
[7]孙 冰,杨亚勤,韩 伟,等.自发荧光支气管镜在肺癌早期诊断中的应用[J].新乡医学院学报,2013,(03):223.
[8]屈亚云,武莉芳,张秀敏,等.依达拉奉对肺癌胸腔镜手术中单肺通气相关肺损伤的保护作用[J].新乡医学院学报,2016,(12):1054.[doi:10.7683/xxyxyxb.2016.12.010]
[9]郭煜颍,张 敏,刘彦廷,等.小分子酪氨酸激酶抑制剂安罗替尼在肺癌治疗中的应用研究进展[J].新乡医学院学报,2021,38(10):986.[doi:10.7683/xxyxyxb.2021.10.018]
[10]周 威,陈贡斌,刘海燕,等.黄芪甲苷对乌拉坦诱导肺癌小鼠的防治作用及其机制[J].新乡医学院学报,2021,38(1):018.[doi:10.7683/xxyxyxb.2021.01.004]
 ZHOU Wei,CHEN Gongbin,LIU Haiyan,et al.Preventive and therapeutic effects of astragaloside IV on urethane induced lung cancer in mice and its mechanism[J].Journal of Xinxiang Medical University,2021,38(11):018.[doi:10.7683/xxyxyxb.2021.01.004]

更新日期/Last Update: 2018-11-05